References
- Bröker M, Bukovski S, Culic D, Jacobsson S, Kolou M, Kuusi, M, Simões MJ, Skozynska Toropainen M, Taha M-K, Tzanakaki G. Meningococcal serogoup Y emergence in Europe. High importance in some European regions in 2012. Hum Vacc Immunother 2014; 10:1725-28; PMID:24608912; http://dx.doi.org/10.4161/hv.28206
- Web pages of national public institutes are not listed here, because many of them are in national languages, but not published in English. Readers interested in the appropriate documents or links are requested to approach the corresponding author
- Bröker M, Jacobsson S, Kuusi M, Pace D, Simões MJ, Skoczynska A, Taha M-K, Toropainen M, Tzanakaki G. Meningococcal serogoup Y in Europe. Update 2011. Hum Vacc Immunother 2012; 8:1907-11; PMID:23032167; http://dx.doi.org/10.4161/hv.21794
- Haut Conseil de la Santé Publique, Jan. 20, 2015. Vaccination contre les infections invasives à méningocoques de sérogroupe C : recommendations du Haut Conseil de la Santé Publique en situation de pénurie de vaccins – Point d'information. http://www.ansm.sante.fr/S-informer/Actualite
- European Centre for Disease Prevention and Control (ECDC). Surveillance of invasive bacterial diseases in Europe 2008/2009. Stockholm, www.ecdc.europa.eu, 2011
- Krauland MG, Dunning Hotopp JC, Riley DR, Daugherty SC, Marsh JW, Messonnier NE, Mayer LW, Tettelin H, Harrison LH. Whole genome sequencing to investigate the emergence of clonal complex 23 Neisseria meningitidis serogroup Y disease in the United States. PLoS One 2012; 7:e35699; PMID:22558202; http://dx.doi.org/10.1371/journal.pone.0035699
- McEllistrem MC, Kolano JA, Pass MA, Caugant DA, Mendelsohn AB, Pacheco AGF, Shutt KA, Razeq J, Harrison LH, and the Maryland Emerging Infections Program. Correlating epidemiologic trends with the genotypes causing meningococcal disease, Maryland. Emerg Infect Dis 2004; 10: 451-56; PMID:15109412
- Noah N, Henderson B. Surveillance of bacterial meningitis in Europe 1998/99. Communicable Disease Surveillance Centre. Europ Bact Mening Surveil Project www.phls.co.uk, 2001
- Peruski AH, Kludt P, Patel RS, DeMaria A. Secular trends in invasive meningococcal disease, Massachusetts, 1998–2011: what happened to invasive disease?. Epidemiol Infect 2014; 142: 2483-90; PMID:25372225; http://dx.doi.org/10.1017/S0950268814000259
- Ladhani SN, Beebeejaum K, Lucidarme J, Campbell H, Gray S, Kaczmarski E, Ramsay ME, Borrow R. Increase in endemic Neisseria meningitidis capsular group W ST-11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis 2015; 60:578-85; PMID:25389259
- Joint Committee on Vaccination and Immunisation. Minutes of the meeting on 4 February 2015. https://app.box.com/s/iddfb4ppwkmtjusir2tc#/s/iddfb4 ppwkmtjusir2tc/1/2199012147/27417264008/1?&_suid=142674966595006959824307533589
- Vernikos G, Medini D. Bexsero© chronicle. Pathog Glob Health 2014; 108: 305-11; PMID:25417906; http://dx.doi.org/10.1179/2047773214Y.0000000162
- Tomei S, Biolchi A, Brunelli B, De Angelis G, Moschioni M, Masignani V, Budroni S, Claus H, Vogel H, Taha M-K, et al. Potential coverage of the Bexsero MenB vaccine on non-B meningococci. XIXth Intl Pathogenic Neisseria Conference (IPNC) October 12-17, 2014, poster no. 30.
- Richmond P, Marsahll H, Nissen M, Jiang Q, Jansen K, Garcés-Sánchez M. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents. A randomized, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:597-607; PMID:22569484; http://dx.doi.org/10.1016/S1473-3099(12)70087-7
- Jeppesen CA, Snape MD, Robinson H, Gossger N, John TM, Voysey M, Ladhani S, Okike IO, Oeser C, Kent A et al. Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. J Infect 2015; 71:43-54; PMID:25709085; http://dx.doi.org/10.1016/j.jinf.2015.02.006